Loading…
Loading…
M Analytical LLC
We are a biotech R&D team focused on discovery, synthesis strategy, and early-stage development for therapeutic and tool compounds.
Our work spans medicinal chemistry, peptide design, and analytical support so programs move from idea to lead candidate with clear decisions at each step.
Hit-to-lead exploration, scaffold optimization, and developability-oriented synthesis routes.
Peptide and peptidomimetic design, including stability, potency, and manufacturability considerations.
We work with partners who need rigorous science, transparent milestones, and a practical path from discovery to the next value inflection.
Service lines and development focus areas we support—med chem, peptides, analytical, ADME-aware design, preformulation, and more. Scoping is always program-specific; this is a map of our strengths, not a retail catalog.
Iterative design cycles around potency, selectivity, and off-target risk.
DetailsScout routes that survive the next order-of-magnitude in scale and complexity.
DetailsFrom linear to constrained peptides and peptidomimetic design.
DetailsPurity, identity, and method development that support chemistry decisions.
DetailsBuild molecules that are testable, not just potent.
DetailsChemistry and analytical alignment for developability and safety.
DetailsSolids, salts, and early formulation risks.
DetailsR&D for ligases, E3 connectors, and linker design.
DetailsRight compounds tested in the right order.
DetailsAll 21R&D areas — from med chem and solid-state to AI-aware design, isotope strategy, and IND-oriented packages.
R&D in context: oncology, metabolic, CNS, rare disease, and more—not therapeutic claims, but the kinds of biology where our chemistry and peptide work is most often applied.
Small-molecule and peptide programs where selectivity, combination logic, and resistance mechanisms matter in lead design.
Read moreLigands and peptides where exposure, organ specificity, and chronic-dosing developability are design drivers.
Read moreChemistry and peptide design with brain exposure, efflux, and CNS safety margins in view.
Read moreAccelerated timelines and material efficiency when every batch counts.
Read moreSelectivity against host targets, resistance pathway awareness, and route feasibility for short-course regimens.
Read moreRigorous chemistry for mechanistic and target-validation work, not just potency on a single assay.
Read morePrograms where hemodynamics, organ perfusion, and long-term organ safety shape chemistry and peptide choices.
Read moreApplication focus page — full context for each area.
We help teams make progress in stages—each with explicit outputs—so you can fund, partner, or pivot on evidence, not hope.
Step 1
Biology, constraints, and success criteria for the next milestone.
Step 2
Compound or peptide series, test plans, and risk factors to watch.
Step 3
Rigorous execution, characterization, and iteration as data accrues.
Step 4
Comparative readouts, recommended next steps, and handoff-ready materials.
See our engagement model in more detail.
Practical science, direct communication, and a bias toward program-level outcomes—not one-off pretty structures.
We structure deliverables so they plug into your governance, diligence, and portfolio reviews.
Chemistry, peptide design, and analytical work stay aligned with DMPK, safety, and scale-up considerations where relevant.
Milestones, risks, and tradeoffs are explicit before heavy spend.
Headquartered in Sheridan, we collaborate with companies and institutions across the U.S. and internationally.